About ixazomib eq to ixazomib citrate
Oral proteasome inhibitor
Used for
- Treats multiple myeloma with lenalidomide and dexamethasone after at least one prior treatment.
Usual adult dose
Usual dose: 4 mg by mouth once weekly on days 1, 8, and 15 of a 28-day cycle, with lenalidomide and dexamethasone. Dose may be reduced for side effects.
Common side effects
- Diarrhea, constipation, nausea, or vomiting
- Low platelet counts, which can increase bleeding risk
- Rash or swelling
- Nerve problems, including numbness or tingling
Important warnings
- Can cause low blood counts, serious infections, or bleeding.
- May cause severe skin reactions or new or worsening nerve problems.
- Can harm an unborn baby; effective contraception is required during treatment.
- Capsules must be swallowed whole; avoid contact with capsule contents.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for 90 days after the last dose; effective contraception is recommended.
Breastfeeding
Breastfeeding is not recommended during treatment or for 90 days after the last dose.
Interactions
- Strong CYP3A inducers, such as rifampin or carbamazepine, can lower ixazomib levels and reduce effectiveness.
- St. John’s wort may lower ixazomib levels; avoid use.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.